PT - JOURNAL ARTICLE AU - Adam Mor AU - Clifton Bingham, 3rd AU - Laura Barisoni AU - Eileen Lydon AU - H Michael Belmont TI - Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. DP - 2005 Apr 01 TA - The Journal of Rheumatology PG - 740--743 VI - 32 IP - 4 4099 - http://www.jrheum.org/content/32/4/740.short 4100 - http://www.jrheum.org/content/32/4/740.full SO - J Rheumatol2005 Apr 01; 32 AB - Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.